Semaglutide (Ozempic) and obesity. A comprehensive guide for aestheticians
From disrupted epidermal barriers to diseases such as psoriasis and hidradenitis suppurativa, it further explores how licensed cosmetologists emerge as health advocates and examines semaglutide's mechanism, efficacy, and unintended consequences of popularity.
Abstract
Obesity is a complex interplay of biological, genetic, behavioural, and environmental factors. Going beyond the con- ventional Body Mass Index (BMI) evaluation, the complex relationship between obesity and skin diseases unveils the evolving role of aesthetics in health promotion. Adipose tissue, traditionally seen as an energy reservoir, is unveiled as a dynamic endocrine organ, playing a crucial role in the pathophysiological mechanisms of insulin resistance and metabolic syndrome. This article navigates the skin-deep impact of obesity and unravelling its influence on dermato- logical challenges. From disrupted epidermal barriers to diseases such as psoriasis and hidradenitis suppurativa, it further explores how licensed cosmetologists emerge as health advocates. For what is more, semaglutide, a ground- breaking GLP-1 agonist, takes the spotlight, tracing its journey from FDA approval for type 2 diabetes to its recent endorsement for obesity. The article examines its mechanism, efficacy, and unintended consequences of popularity, emphasizing the need for responsible medication use.